

Anti-IL-2R alpha (Daclizumab), Human IgG1 Antibody

CATALOG NO:	A1099-200
ALTERNATIVE NAMES:	Interleukin-2 receptor subunit alpha; IL-2 receptor subunit alpha; IL-2R subunit alpha; IL-2-RA; IL2-RA; TAC antigen; p55; CD25.
AMOUNT:	200 µg
ISOTYPE / FORMAT:	Human IgG1, kappa
CLONALITY:	Monoclonal
CLONE:	Daclizumab
SPECIES REACTIVITY:	Human
IMMUNOGEN:	Cultured T-cells derived from a patient with Mycosis fungoides.
FORM:	Liquid
SPECIFICITY:	Binds to p55 chain of IL2R on human T cells, Tac antigen, which is expressed on T cells activated by mitogens, soluble antigens, and alloantigens but not on resting T cells, thymocytes, B cells, monocytes, activated B cells, leukemic T cell blasts from patients with acute lymphoblastic leukemia, and long-term T cell lines.
PURIFICATION:	Affinity purified using Protein A
FORMULATION:	Supplied in PBS with preservative (0.02% Proclin 300)
STORAGE CONDITIONS:	Store at 4°C for upto 3 months. For long term storage, aliquot and freeze at -20°C. Avoid repeated freeze/thaw cycles.
DESCRIPTION:	Recombinant monoclonal antibody to IL-2R. Manufactured using Recombinant Platform with variable regions (i.e. specificity) from the therapeutic antibody Daclizumab.
BACKGROUND:	Receptor for interleukin-2. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T-cells.
APPLICATION:	FC
REFERENCE:	Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, Avdaloovic NM, Levitt M, Junghans R, Waldmann TA. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci U S A. 1989 Dec; 86 (24):10029-33. P

RELATED PRODUCTS:

- Anti-VEGF (Bevacizumab), humanized Antibody (**Cat. No. A1045-100**)
- Anti-HER2 (Trastuzumab), humanized Antibody (**Cat. No. A1046-100**)
- Anti-EGFR (Cetuximab), Chimeric Antibody (**Cat. No. A1047-100**)
- Anti-TNF-α (Adalimumab), humanized Antibody (**Cat. No. A1048-100**)
- Anti-CD20 (Rituximab), Chimeric Antibody (**Cat. No. A1049-100**)
- Anti-EGFR (Panitumumab), humanized antibody (**Cat. No. A1050-100**)
- Anti-OX40L (Oxelumab), Human IgG1 Antibody (**Cat. No. A1088-200**)
- Anti-CD11a (Efalizumab), Human IgG1 Antibody (**Cat. No. A1089-200**)
- Anti-EGFR (Matuzumab), Human IgG1 Antibody (**Cat. No. A1090-200**)
- Anti-CD4 (Clenoliximab), Human IgG4 Antibody (**Cat. No. A1091-200**)
- Anti-alpha 5 beta1 Integrin (Volociximab), Human IgG4 Antibody (**Cat. No. A1092-200**)
- Anti-TNF alpha (Humicade), Human IgG4 Antibody (**Cat. No. A1093-200**)
- Anti-CD40L (Ruplizumab), Human IgG1 Antibody (**Cat. No. A1094-200**)
- Anti-Human Ephrin Type A receptor 2 (1C1), Human IgG1 Antibody (**Cat. No. A1095-200**)
- Anti-Carcinoembryonic antigen (Arcitumomab), Human IgG1 Antibody (**Cat. No. A1096-200**)
- Anti-TNF alpha (Infliximab), Human IgG1 Antibody (**Cat. No. A1097-200**)
- Anti-IL-2R alpha (CD25) (Basiliximab), Human IgG1 Antibody (**Cat. No. A1098-200**)

FOR RESEARCH USE ONLY! Not to be used on humans.